Complications and use of intracranial pressure monitoring in patients with acute liver failure and severe encephalopathy

• Published in: Liver transplantation Vol. 11; no. 12; pp. 1581 - 1589
• Main Authors: Vaquero, Javier, Fontana, Robert J., Larson, Anne M., Bass, Nathan M.T., Davern, Timothy J., Shakil, A. Obaid, Han, Steven, Harrison, M. Edwyn, Stravitz, Todd R., Muñoz, Santiago, Brown, Robert, Lee, William M., Blei, Andres T.
• Format: Journal Article
• Language: English
• Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.12.2005
• Subjects: Adult; Female; Hepatic Encephalopathy - complications; Hepatic Encephalopathy - mortality; Hepatic Encephalopathy - physiopathology; Humans; Intracranial Hypertension - etiology; Intracranial Hypertension - mortality; Intracranial Hypertension - physiopathology; Intracranial Pressure - physiology; Liver Failure, Acute - complications; Liver Failure, Acute - physiopathology; Liver Failure, Acute - surgery; Liver Transplantation; Male; Monitoring, Physiologic - adverse effects; Monitoring, Physiologic - methods; Prospective Studies; Risk Factors; Survival Rate; Treatment Outcome
• ISSN: 1527-6465; 1527-6473
• DOI: 10.1002/lt.20625

Monitoring of intracranial pressure (ICP) in acute liver failure (ALF) is controversial as a result of the reported complication risk (∼20%) and limited therapeutic options for intracranial hypertension. Using prospectively collected information from 332 patients with ALF and severe encephalopathy, we evaluated a recent experience with ICP monitoring in the 24 centers constituting the U.S. ALF Study Group. Special attention was given to the rate of complications, changes in management, and outcome after liver transplantation (LT). ICP monitoring was used in 92 patients (28% of the cohort), but the frequency of monitoring differed between centers (P < 0.001). ICP monitoring was strongly associated with the indication of LT (P < 0.001). A survey performed in a subset of 58 patients with ICP monitoring revealed intracranial hemorrhage in 10.3% of the cohort, half of the complications being incidental radiological findings. However, intracranial bleeding could have contributed to the demise of 2 patients. In subjects listed for LT, ICP monitoring was associated with a higher proportion of subjects receiving vasopressors and ICP‐related medications. The 30‐day survival post‐LT was similar in both monitored and nonmonitored groups (85% vs. 85%). In conclusion, the risk of intracranial hemorrhage following ICP monitoring may have decreased in the last decade, but major complications are still present. In the absence of ICP monitoring, however, patients listed for LT appear to be treated less aggressively for intracranial hypertension. In view of the high 30‐day survival rate after LT, future studies of the impact of intracranial hypertension should also focus on long‐term neurological recovery from ALF. (Liver Transpl 2005;11:1581–1589.)